Cargando…

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

Detalles Bibliográficos
Autores principales:	Kumar, Priyadarshini, Uppal, Manik, Xiao, Wenbin, Dogan, Ahmet, Roshal, Mikhail, Gao, Qi, Aypar, Umut, Zhang, Yanming, Arcila, Maria E., Moung, Christine, Yao, Jinjuan, Nafa, Khedoudja, Yu, Wayne, Syed, Mustafa H., Park, Jae, Kumar, Anita, Ho, Caleb
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493823/ https://www.ncbi.nlm.nih.gov/pubmed/31612754 http://dx.doi.org/10.1080/10428194.2019.1675876

Ejemplares similares

The t(11;14)(q13;q32)/CCND1–IGH translocation in chronic lymphocytic leukaemia/small lymphocytic lymphoma: an unusual genetic aberration during the natural clinical course
por: Liu, Ying, et al.
Publicado: (2019)

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter's Transformation and CLL/SLL
por: Kadkol, Shrihari S., et al.
Publicado: (2021)

A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia
por: Yao, Jinjuan, et al.
Publicado: (2017)

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry
por: Ho, Caleb, et al.
Publicado: (2021)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

PB1911: CYTOGENOMIC INTEGRATIVE ANALYSIS OF CLL/SLL PATIENTS AT DISEASE PROGRESSION.
por: García-Serra, Rocío, et al.
Publicado: (2023)

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry
por: Mato, Anthony R., et al.
Publicado: (2022)

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019
por: Kittai, Adam S., et al.
Publicado: (2022)

Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma
por: Tashkandi, Hammad, et al.
Publicado: (2019)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis
por: Vassilopoulos, Stephanos, et al.
Publicado: (2022)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Myeloid/lymphoid neoplasms with eosinophilia/basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition
por: Yao, Jinjuan, et al.
Publicado: (2020)

The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology
por: Kastenbaum, Hannah A., et al.
Publicado: (2010)

Co-Occurrence of EBV-Positive Mucocutaneous Ulcer (EBV-MCU) and CLL/SLL in the Head and Neck Region
por: Bott, Patricia, et al.
Publicado: (2022)

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

Bilateral breast implant associated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A case report
por: Bletsis, Patrick P., et al.
Publicado: (2020)

LHCb : b -> sll
por: Tou, Da Yu
Publicado: (2020)

Folliculocentric lymphocytic hypersensitivity reactions in CLL/SLL patients: A unique clinicopathologic entity amongst non‐specific hypersensitivity reactions
por: Abbott, James, et al.
Publicado: (2023)

b→sll decays at LHCb
por: Serra, Nicola
Publicado: (2023)

$b \to sll$ exclusive decays
por: Owen, p
Publicado: (2014)

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
por: Brown, J R, et al.
Publicado: (2018)

MUM1/IRF4 Expression Is an Unfavorable Prognostic Factor in B‐Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
por: Ito, Masato, et al.
Publicado: (2002)

PB2696: QUALITATIVE INTERVIEWS TO DESCRIBE BURDEN IN PATIENTS (PT) WITH THIRD-LINE OR LATER CLL/SLL WITH PRIOR EXPOSURE TO BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
por: Priyadarshini, Masoom, et al.
Publicado: (2023)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC
por: Decker, William K., et al.
Publicado: (2012)

Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms
por: Gao, Qi, et al.
Publicado: (2018)

$b\to sll$ and radaiative decays at LHCb
por: Polci, Francesco
Publicado: (2016)

Study of $b \to sll$ decays at ATLAS
por: Bona, Marcella
Publicado: (2017)

$b$ → $sℓℓ$ measurements from LHCb
por: Borsato, Martino
Publicado: (2021)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

CD160 receptor in CLL: Current state and future avenues
por: Oumeslakht, Loubna, et al.
Publicado: (2022)

Clonal expansion in B-CLL: Fungal drivers or self-service?
por: Greaves, Mel
Publicado: (2013)

The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo
por: Scialdone, Annarita, et al.
Publicado: (2017)

P1459: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA (B-NHL), AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL)
por: Roddie, C., et al.
Publicado: (2022)

Angular analyses of b → sll transitions at CMS
por: Li, Linwei
Publicado: (2019)

Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K)
por: Grygalewicz, Beata, et al.
Publicado: (2016)

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
por: Burger, Jan A., et al.
Publicado: (2019)

Clinical course of COVID-19 in a patient with refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) under ibrutinib therapy: a case report
por: Cecyn, Karin Zattar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9g0tntctrn87aatrt9bcuon759